Host-guest complexation. 60. Rigidly hollow hosts that encapsulate small molecules
摘要:
New chiral host systems 1 and 2 possessing C3 symmetry have been designed and synthesized. Molecular models of 1 and 2 indicate they contain small enforced cavities and three portals complementary to small molecules. The crystal structure of 1.2CH3CN shows one molecule of CH3CN is encapsulated and the second exists as a solvate. A crystal structure of 2.2CH3OH shows one CH3OH molecule is encapsulated and a second serves as a solvate. A crystal structure of 2.CH2Cl2 shows the host to be empty and that the CH2Cl2 acts as a solvate to provide (by disorder) a C3 pattern about the C3 axis of the host. In CDCl3 solutions (CDCl3 is too large to occupy its cavity), 1 complexed O2, N2, H2O, and CO2 readily and reversibly (H-1 NMR spectra), particularly at low temperatures. In CDCl3 solution, 1 binds CH3OH with K(a) = 10 M-1, DELTA-G-degrees 295 = -1.4 kcal mol-1, DELTA-H congruent-to -6.6 kcal mol-1, and DELTA-S congruent-to -18 cal mol-1 K-1. It also binds CH3CN, but much more weakly. Triamine 2 in CDCl3 binds O2, N2, and H2O weakly and CH3OH with a K(a) = 47 M-1, DELTA-G-degrees 295 = -2.3 kcal mol-1, DELTA-H congruent-to -8.5 kcal mol-1, and DELTA-S congruent-to -21 cal mol-1 K-1. This host binds CH3CN at 295 K with a K(a) in the range of 1-10 M-1, and CH3CH2OH with a K(a) < 5 M-1. The H-1 NMR signals of the guest's CH2 group of 2.CH3CH2OH indicate the protons to be diastereotopic. The half-life for decomplexation of 2.CH3CH2OH was about 40 min at 25-degrees-C.
Compounds having the structural formula I
1
or a pharmaceutically acceptable salt thereof, wherein
R is
2
R
1
, R
2
, R
3
, R
4
and R
5
are H, alkyl or alkoxyalkyl;
R
6
is H, alkyl, hydroxyalkyl or —CH
2
F;
R
7
, R
8
and R
9
are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF
3
; and
Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed.
Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity
[EN] CIS-IMIDAZOLINES AS MDM2 INHIBITORS<br/>[FR] CIS-IMIDAZOLINES INHIBITEURS DE MDM2
申请人:HOFFMANN LA ROCHE
公开号:WO2003051360A1
公开(公告)日:2003-06-26
The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity (I) (II).
The aim of the present invention is to provide a multi-branched polymer, in which branch terminals can be easily modified and which have a high degree of branching and narrow dispersion. By polymerizing a compound having 2 or more polymerization-initiation sites and polymerizable unsaturated bonds with a living radical polymerization method using a metal catalyst, it is possible to produce a multi-branched polymer with narrow dispersion and a high degree of branching and having repeating units represented by the formula (I):
wherein R
1
to R
3
each independently represents hydrogen or a hydrocarbon group, R
1
may be bonded to R
3
to form a ring; X represents a connecting group having a valence of 3 or higher; Y may be the same or different and each represents a functional group which may have a halogen atom at a terminal thereof; and a is an integer of 2 or larger.
The aim of the present invention is to provide a multi-branched polymer, in which branch terminals can be easily modified and which have a high degree of branching and narrow dispersion. By polymerizing a compound having 2 or more polymerization-initiation sites and polymerizable unsaturated bonds with a living radical polymerization method using a metal catalyst, it is possible to produce a multi-branched polymer with narrow dispersion and a high degree of branching and having repeating units represented by the formula (I):
wherein R1 to R3 each independently represents hydrogen or a hydrocarbon group, R1 may be bonded to R3 to form a ring; X represents a connecting group having a valence of 3 or higher; Y may be the same or different and each represents a functional group which may have a halogen atom at a terminal thereof; and a is an integer of 2 or larger.